Forward Pharma is ...
Forward Pharma is a privately held biotechnology company, founded in 2005 in Copenhagen, Denmark. The company is focused on the immunomodulatory compound dimethyl fumarate and derivatives, for applications as pharmaceutical drug product in lead areas of dermatology, neurology and oncology.
Read more
FP187 (dimethyl fumarate) is …
FP187 (dimethyl fumarate) is Forward Pharma’s oral fumaric acid ester (FAE) late-stage clinical product candidate in psoriasis and multiple sclerosis.
FP187
- Has completed one pivotal registration trial
- Planned filing in psoriasis in EU 2013/2014
Prof. Dr. Kristian Reich on fumaric acid ester (FAE) therapy in psoriasis, Hamburg, 15.08.2012
 |
||
News room17.12.2012 Mr. J. Kevin Buchi, former CEO of Cephalon Inc., has been appointed to the Board of Directors of Forward Pharma A/S. 30.11.2012 Forward Pharma has completed its pivotal registration study for its primary development compound FP187. |
|
Science of dimethyl fumarateDimethyl fumarate – only an anti-psoriatic medication? Meissner M et al., JDDG 2012. Link Dimethyl Fumarate Inhibits Dendritic Cell Maturation via NF-kB and ERK1/2 and MSK1 Signaling. Peng H et al., JBC 2012. Link Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. Ghoreschi K et al., J Exp Med 2011. Link Microdialysis documents changes in the micromilieu of psoriatic plaques under continuous systemic therapy. Salgo R et al., Exp Dermatol. 2011. Link Dimethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression. Gesser B et al., Inflamm. Res. 2011. Link |
|
 |
|
|